EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a “rare in rare” scenario

Nicolò Danesin iD, Greta Scapinello, Dorella Del Prete, Elena Naso, Tamara Berno, Andrea Visentin iD, Laura Bonaldi, Annalisa Martines iD, Roberta Bertorelle, Fabrizio Vianello, Carmela Gurrieri iD, Renato Zambello und 6 weitere

Cancer Reports · 2024

DOI: 10.1002/cnr2.2062 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2024. Verfasst von Nicolò Danesin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Medicine, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Renal injury related to Waldenström macroglobulinemia (WM) occurs in approximately 3% of patients. Kidney biopsy is crucial to discriminate between distinct histopathological entities such as glomerular (amyloidotic and non‐amyloidotic), tubulo‐interstitial and non‐paraprotein mediated renal damage. In this context, disease characterization, management, relationship between renal, and hematological response have been poorly explored. We collected clinical, genetic and laboratory data of seven cases of biopsy‐proven renal involvement by WM managed at our academic center and focused on three cases we judged paradigmatic discussing their histopathological patterns, clinical features, and therapeutic options. Case In this illustrative case series, we confirm that serum creatinine levels and 24 h proteinuria are parameters that when altered should prompt the clinical suspicion of WM‐related renal involvement, even if at present there are not precise cut‐off levels recommending the execution of a renal biopsy. In our series AL Amyloidosis ( n = 3/7) and tubulo‐interstitial infiltration by lymphoma cells ( n = 3/7) were the two more represented entities. BTKi did not seem to improve renal function (Case 1), while bortezomib‐based regimens demonstrated a beneficial activity on the hematological and organ response, even when used as second‐line therapy after chemoimmunotherapy (Case 3) and also with coexistence of anti‐MAG neuropathy (Case 2). In case of poor response to bortezomib, standard chemoimmunotherapy (CIT), such as rituximab‐bendamustine, represents an effective option (Case 1, 6, and 7). In our series, CIT generates durable responses more frequently in cases with amyloidogenic renal damage (Case 1, 5, and 7).

Conclusion

In this illustrative case series, we confirm that serum creatinine levels and 24 h proteinuria are parameters that when altered should prompt the clinical suspicion of WM‐related renal involvement, even if at present there are not precise cut‐off levels recommending the execution of a renal biopsy. Studies with higher numerosity are needed to better clarify the pathological and clinical features of renal involvement during WM and to determine the potential benefit of different therapeutic regimens according to the histopathological subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaHumansMaleAgedFemaleMiddle AgedKidneyBiopsyBortezomib

Stichwörter der Autor:innen

Waldenström macroglobulinemiaamyloidosiskidney diseaselymphomalymphoproliferative disorders

Substanzen

Bortezomib

Autor:innen und Institutionen

  • Hematology Unit, Department of Medicine, University of Padova, Padova, Italy.
  • Nephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padova, Italy.
  • Immunology and Molecular Oncology Diagnostic Unit, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
  • Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy.
  • Cardiovascular Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Padova, Italy.

ORCID-Profile: Nicolò Danesin, Andrea Visentin, Annalisa Martines, Carmela Gurrieri, Livio Trentin, Francesco Piazza

Zitieren

APA

Danesin, N., Scapinello, G., Del Prete, D., Naso, E., Berno, T., Visentin, A., Bonaldi, L., Martines, A., Bertorelle, R., Vianello, F., Gurrieri, C., Zambello, R., Castellani, C., Fedrigo, M., Rizzo, S., Angelini, A., Trentin, L., & Piazza, F. (2024). When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a “rare in rare” scenario. Cancer Reports. https://doi.org/10.1002/cnr2.2062

Vancouver

Danesin N, Scapinello G, Del Prete D, Naso E, Berno T, Visentin A, et al. When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a “rare in rare” scenario. Cancer Reports. 2024. doi:10.1002/cnr2.2062

BibTeX
@article{Danesin2024,
  author = {Danesin, Nicolò and Scapinello, Greta and Del Prete, Dorella and Naso, Elena and Berno, Tamara and Visentin, Andrea and Bonaldi, Laura and Martines, Annalisa and Bertorelle, Roberta and Vianello, Fabrizio and Gurrieri, Carmela and Zambello, Renato and Castellani, Chiara and Fedrigo, Marny and Rizzo, Stefania and Angelini, Annalisa and Trentin, Livio and Piazza, Francesco},
  title = {When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a “rare in rare” scenario},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.2062}
}
Kostenlos starten →